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Transplant recipients may be more susceptible to COVID-19 and itsrelated complications.1-3Despite 
most patients being managed with reduction of immunosuppression, the risk of rejection or graft loss 
does not seem to be increased during COVID-19.1,2,4,5
The use of lymphocyte depleting agents has the inherent potential of impairing lymphocyte 
responses that are required for viral control.6,7 However, their use may be unavoidable in steroid-
resistant rejection. We report the administration of rabbit anti-thymocyte globulin (rATG) for steroid-
resistant acute allograft rejection in two recipients ofsimultaneous pancreas and kidney transplant 
(SPK) who recovered from COVID-19 but continued to have viral shedding. 
A 53-year-old female who underwent SPK on 02/08/2019diagnosed with mild COVID-19 
on06/06/2020without requiringreduction of immunosuppressionwas admitted on 06/26/2020 with 
presumed pancreas allograft rejection due to elevated lipase levels(baseline 4 units/L, on admission 
691 units/L) and fat stranding surrounding both kidney and pancreas allograft on imaging. SARS-
CoV-2 PCR and IgG were positive. Despite treatment with high-dose steroids she had rising lipase 
and worsening enhancement of the pancreas allograft. Given presumed steroid-resistant rejection, 
she received empiric therapy withrATG(total 7.5 mg/kg) with subsequent normalization of lipase 
levels. Clinically, she recovered well without any signs or symptoms of recurrent COVID-19 (Table 
1). 
A 46-year-old male who underwent SPK on 01/21/2017, who was diagnosed with asymptomatic 
COVID-19 on 05/12/2020after his wife tested positive for COVID-19, was admitted on 07/01/2020 for 
management of biopsy proven acute cellular rejection and chronic active antibody-mediated rejection 
with new donor-specific antibodies.His creatinine had increased from baseline 1.3 mg/dL to 8.4 
mg/dL. Repeat SARS-CoV-2 PCR and IgG were positive. He underwent plasma exchange,rituximab, 
IVIGand rATG (total 5 mg/kg). Following plasma exchange he experienced sero-reversion of SARS-
CoV-2 IgG. While his renal function did not respond to therapy, hedidnot experience any signs or 
symptoms of COVID-19. (Table 2)
Neither of our patients had reduction of their immunosuppression and had stable drug levels, 
suggesting that compliance was not associated with the development of rejection. Although 
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the rejection. While steroids can lead to prolonged viral shedding, the use of steroids has been 
shown to reduce mortality in hospitalized patients with severe COVID-19.8,9
Our patients continued to have viral shedding when rejection was diagnosed. Viral shedding has 
been detected up to 119days from symptom initiation and prolonged shedding is not a rare 
phenomenon10. However, the duration of infectivity remains unknown.11Several studies have 
correlated results from PCR and viral cultures. Three different authors independently reported 
positive cultures up to 8 days, while two others havereported positive cultures up to 18 and 20 
days.12-1415,16 A heart transplant recipient with mild COVID-19 3 months after his transplantation, had 
positive viral cultures up to 21 days, while his PCR remained positive up to 35 days.18 Recently, a 
patient with lymphoma and associated B-cell immunodeficiency developed chronic symptomatic 
COVID-19 was found to have positive viral cultures for at least 119 days. The lack of seroconversion 
suggested an important role of humoral responses for the control of SARS-CoV-2. 10
While the current guidelines generally recommend against initiation or augmentations of 
immunosuppression while patients have ongoing SARS-CoV-2 PCR positivity, our patients did not 
experience any signs or symptoms of recurrent COVID-19 suggesting that PCR positivity does not 
necessarily indicate infectivity. However, the management of rejection in patients with recent COVID-
19 and positive SARS-CoV-2 PCR should be individualized.This is particularly useful in the setting of 
heart, lung and liver transplants. 
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Table 1. Timeline of testing and clinical data from patient 1
Table 2. Timeline of testing and clinical data from patient 2
*DSA Pre-Treatment (Day 50) A2 5200; B51 2900, DR 1 5800, DR9 10100, DR 53 12200, DQ9 13300
** DSA 27 days post-Treatment (Day 77) A2 800, DR1 900, DR 9 5000, DR53 23500, DQ9 22600.
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